Treatment strategies for ADHD

Chair: Peter Mason, UK
001 | Psychopharmacology of ADHD medications 
Speaker: Andrew Jay, UK 
002 | Ask the experts: What’s the difference? (moderated Q&A)
Discussants: Caroline Bleakley, UK | Willem Bohlmeijer, The Netherlands | Lotta Borg Skoglund, Sweden | Andrew Jay, UK | Roger McIntyre, Canada
003 | Utilising a choice of ADHD medications in clinical practice 
Speaker: Peter Mason, UK 
004 | Ask the experts: How to optimise ADHD treatment for patients with ADHD (moderated Q&A)
Discussants: Caroline Bleakley, UK | Willem Bohlmeijer, The Netherlands | Lotta Borg Skoglund, Sweden | Andrew Jay, UK | Roger McIntyre, Canada
005 | Closing comments 

^{Information in this symposium is for healthcare professionals outside of US only. Takeda medicines will be discussed at this symposium. Some of the medicines discussed in this symposium may not be available/licensed for ADHD in some countries. Clinicians should refer to the respective Summary of Product Characteristics (SmPC) in their country before prescribing. Prescribing information for Takeda products will be available at Takeda’s symposium and exhibition booth at this congress.}

ADHD – The Patient’s Perspective

Moderator: Dora Wynchank, The Netherlands
001 | Diagnosis and Treatment of ADHD in Europe, Survey 2020
Speaker: Carola Stivala, Malta
002 | A million miles an hour - a day in the life of an ADHD patient
Speaker: Kobus van Rensburg, UK
003 | Questions & Discussion